PRAXIS PRECISION MEDICINES, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- PRAXIS PRECISION MEDICINES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 48.80K shares.
- PRAXIS PRECISION MEDICINES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 25.40K shares, a 76.13% increase year-over-year.
- PRAXIS PRECISION MEDICINES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 185.38K shares, a 408.96% increase year-over-year.
- PRAXIS PRECISION MEDICINES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 20.45K shares, a 311.49% increase year-over-year.
- PRAXIS PRECISION MEDICINES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 220.26K shares, a 387.55% increase from fiscal 2024.
- PRAXIS PRECISION MEDICINES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 45.18K shares, a 1276.93% increase from fiscal 2023.
- PRAXIS PRECISION MEDICINES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 3.28K shares, a 98.76% decline from fiscal 2022.
- PRAXIS PRECISION MEDICINES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 265.66K shares, a 70.15% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 48.80K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 280.04K shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 25.40K shares 10-Q · filed 2026-05-07 | 231.24K shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 185.38K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | 220.26K shares 10-K · filed 2026-02-19 |
| 2025-09-30 | 20.45K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 71.30K shares derived: sum of 4 quarters · filed 2025-11-05 |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | 55.82K shares derived: sum of 4 quarters · filed 2025-08-04 |
| 2025-03-31 | 14.42K shares 10-Q · filed 2025-05-02 | 55.97K shares derived: sum of 4 quarters · filed 2025-05-02 |
| 2024-12-31 | 36.42K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | 45.18K shares 10-K · filed 2025-02-28 |
| 2024-09-30 | 4.97K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -37.28K shares derived: sum of 4 quarters · filed 2024-11-06 |
| 2024-06-30 | 148.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -37.58K shares derived: sum of 4 quarters · filed 2024-08-13 |
| 2024-03-31 | 3.63K shares 10-Q · filed 2024-05-13 | -37.73K shares derived: sum of 4 quarters · filed 2024-05-13 |
| 2023-12-31 | -46.03K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | 3.28K shares 10-K · filed 2024-03-05 |
| 2023-09-30 | 4.67K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | 49.32K shares derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | 224.88K shares derived: sum of 4 quarters · filed 2023-08-09 |
| 2023-03-31 | 44.64K shares 10-Q · filed 2023-05-11 | 238.03K shares derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-07 | 265.66K shares 10-K · filed 2023-02-07 |
| 2022-09-30 | 180.24K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | 390.11K shares derived: sum of 4 quarters · filed 2022-11-09 |
| 2022-06-30 | 13.14K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | 300.78K shares derived: sum of 4 quarters · filed 2022-08-08 |
| 2022-03-31 | 72.28K shares 10-Q · filed 2022-05-09 | 609.75K shares derived: sum of 4 quarters · filed 2022-05-09 |
| 2021-12-31 | 124.45K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | 889.97K shares 10-K · filed 2022-02-28 |
| 2021-09-30 | 90.91K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | 784.40K shares derived: sum of 4 quarters · filed 2021-11-03 |
| 2021-06-30 | 322.11K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | |
| 2021-03-31 | 352.51K shares 10-Q · filed 2021-05-11 | |
| 2020-12-31 | 18.87K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-17 | 30.50K shares 10-K · filed 2021-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |